Inhibikase Therapeutics Announces Pricing Of $110M Private Placement To Advance IkT-001Pro, Into A Late-Stage Trial In Pulmonary Arterial Hypertension; Aggregate Investment Of Up To ~$275M By Healthcare-Focused Investment Funds, Led By Soleus Capital
Portfolio Pulse from Benzinga Newsdesk
Inhibikase Therapeutics has announced a $110 million private placement to fund a Phase 2b trial for its drug IkT-001Pro in pulmonary arterial hypertension. The investment, led by Soleus Capital, is part of a larger $275 million commitment from healthcare-focused funds. The company is issuing shares and warrants as part of the financing.
October 09, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inhibikase Therapeutics has secured $110 million in a private placement to advance its drug IkT-001Pro into a Phase 2b trial for pulmonary arterial hypertension. This financing is part of a larger $275 million investment led by Soleus Capital, involving the issuance of shares and warrants.
The $110 million private placement is a significant financial boost for Inhibikase, allowing it to advance its drug IkT-001Pro into late-stage trials. The involvement of major healthcare-focused funds and the issuance of shares and warrants suggest strong investor confidence, likely leading to a positive short-term impact on IKT's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100